

# Ulcerative Colitis Market Size Worth \$10.8 Billion, Globally, by 2030 at 5.7% CAGR

*Ulcerative colitis market report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics.*



PORTLAND, OREGON, UNITED STATES, September 20, 2022

/EINPresswire.com/ -- [Ulcerative colitis market](#) was valued at \$6.2 billion in 2020, and is estimated to reach \$10.8 billion by 2030, growing at a CAGR

of 5.7% from 2021 to 2030. Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules.

□□□□□□□□ □□□□□□ □□□□□□ <https://www.alliedmarketresearch.com/request-sample/3965>

Factor that drives the ulcerative colitis market growth include increase in number of inflammatory bowel disease. In addition, rise in number of ulcerative colitis incidences propels growth of the market. However, rise in burden of inflammatory bowel disease increases growth of the market. Furthermore, the Food and Drug Administration (FDA) aims to enhance availability of reliable and effective drugs to meet public health needs and increase access to treat consumers.

Moreover, rise in development of pharmaceutical and medical device industries and improvement in healthcare spending are anticipated to drive growth of the ulcerative colitis market. In addition, increase in development of new product launches led to rise in the healthcare sector, thereby propelling growth of the market.

Moreover, governments initiatives for development of new drugs and healthcare sector for manufacturing of ulcerative colitis drugs are the key factors that boost growth of the market.

For instance, in May 2018, Takeda Pharmaceutical Company Ltd. and Shire Plc. announced that Takeda had reached an agreement on the terms of proposed offer to acquire all of outstanding shares and future common shares of Shire Plc. In addition, in June 2019, Abbvie completed the acquisition of Allergan to expand its product portfolio to offer extensively advanced treatments

for patients. Allergan launched a monoclonal antibody called brazikumab, which is used in the treatment of ulcerative colitis. Thus, increase in development of new drugs drives the substantial growth of the ulcerative colitis market size during forecast period.

□□□ □□□□□□□□ □□□□□□□□ <https://www.alliedmarketresearch.com/purchase-enquiry/3965>

By molecule type, the market is divided into small molecules and biologics. The small molecule segment acquired top position in the ulcerative colitis industry in 2020, and this trend is expected to continue during the forecast period, owing to large number of drugs offered by key players and increase in use of drugs for the treatment of inflammatory gastrointestinal disorder. By route of administration, the market is fragmented into oral and injectables.

Region wise, North America accounted for a majority of the global ulcerative colitis market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of inflammatory bowel disease, increase in number of approvals for ulcerative colitis drugs, presence of key players, and advancement in the development of drugs in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in deficiency of vitamin D in the countries, rise in number of geriatric populations, growth in health care expenditures, and rise in adoption of effective drugs.

□□□ □□□□□□□□ □□ □□□ □□□□□□

- By disease type, the mild UC segment was the highest contributor to the market in 2020.
- On the basis of molecule type, the small molecule segment dominated the market in 2020, and is expected to continue this trend during the forecast period.
- On the basis of route of administration, the oral segment dominated the market in 2020, and is expected to continue this trend during the forecast period
- Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

□□□□□ □□□□□□□□ □□□□□□□□:

[Computational Biology Market](#)

[Electrosurgery Devices Market](#)

□□□□□ □□□□□□ □□□□□□ □□□□□□□□:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and

achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of the domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa  
Allied Analytics LLP  
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/591800133>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.